ADC Therapeutics SA
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
ADCT$1.67+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
INDEX TO FINANCIAL STATEMENTS
| Audited Financial Statements — ADC Therapeutics SA | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID 1358) | 78 |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | 81 |
| Consolidated Statements of Operation for the fiscal years ended December 31, 2023 and 2022 | 82 |
| Consolidated Statements of Comprehensive Loss for fiscal years ended December 31, 2023 and 2022 | 83 |
| Consolidated Statements of Changes in Shareholders’ Equity (Deficit) for the fiscal years ended December 31, 2023 and 2022 | 84 |
| Consolidated Statements of Cash Flows for the fiscal years ended December 31, 2023 and 2022 | 85 |
| Notes to the Consolidated Financial Statements | 86 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.